RZLT
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Rezolute, Inc. is a late-stage rare disease biopharmaceutical company developing therapies for refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. The company’s lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds to an allosteric site on the insulin receptor to down-modulate insulin receptor activity. This mechanism restores glucose levels in conditions characterized by elevated insulin or insulin-like substances, including congenital and tumor hyperinsulinism. Rezolute is advancing two Phase 3 clinical programs, including the sunRIZE study for congenital hyperinsulinism, and maintains an Expanded Access Program for patients. The company targets pediatric and adult populations suffering from recurrent hypoglycemia, a condition where current standard of care treatments are often suboptimal. Ersodetug has received Orphan Drug Designation in the U.S. and European Union, as well as Rare Pediatric Disease Designation in the U.S. Additionally, the asset holds a priority medicines (PRIME) designation from the European Medicines Agency and an Innovation Passport designation from the UK Innovative Licensing and Access Pathway. The company is engaged in regulatory discussions with the FDA regarding the next steps for a potential marketing application for congenital hyperinsulinism.

Summarised from the company's own disclosures, fiscal year ended Sep 2026

Industry Biotechnology Homepage rezolutebio.com
Sector Healthcare IR page ir.rezolutebio.com
Tags
rare disease, hyperinsulinism, hypoglycemia, monoclonal antibodies, pediatric, congenital hyperinsulinism, tumor hyperinsulinism, insulin receptor, biologics, ersodetug, sunRIZE
Press page ir.rezolutebio.com/news

Metrics

Valuation  
Market cap $ 400.43M
Market cap (USD) $ 400.43M
P/E -5.52
PEG —
P/BV 4.66
P/S —
P/OCF -6.07
P/FCF -5.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -59.0%
ROI -85.9%
ROIC -68.9%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -61.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Assets 112.849M 175.49M 132.737M 123.721M 152.42M 42.609M 10.965M 12.252M 2.503M 10.629M 10.903M 11.263M 7.405M 1.104M
Net profit -77.586M -74.412M -68.459M -51.787M -41.06M -20.902M -20.333M -30.446M -29.862M -20.277M -14.936M -11.362M -9.73M -6.727M
Free cash flow — -69.075M -57.368M -44.653M -39.616M — -24.168M -15.351M — — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.2 4.46 4.3 1.98 3.23 14.27 0.1 — — — — — — —
Price performance 12m 0.17 0.04 1.17 -0.39 -0.77 141.7 — — — — — — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Lease liabilities (USD) — — 0.00 410,000 452,000 188,000 2.48M 2.23M 1.62M 934,000
Cash and deposits (USD) 4.49M 1.65M 11.6M 9.96M 41M 150M 16M 70.4M 94.1M 10.6M
Intangible assets (USD) 44,322 37,030 29,000 0.00 — — — — — —
Right-of-use assets (USD) — — 0.00 383,000 396,000 152,000 2.05M 1.88M 1.35M 769,000
Cash flow detail
Operating cash flow (USD) -13.3M -14.1M -15.3M -24.2M -20.4M -39.6M -44.5M -57.4M -69.1M -64.6M
Purchases of property, plant and equipment (USD) — -6,000 -47,000 0.00 — — -153,000 — — —
Change in payables (cash effect) (USD) — — -931,000 330,000 142,000 -11,000 2.14M 1.08M 1.42M -748,000
Share buybacks (cash effect) (USD) — — — — — — — -3,000 — —
Interest paid (cash effect) (USD) 0.00 0.00 0.00 0.00 -177,000 -1.49M — — — —
Income taxes paid (cash effect) (USD) 0.00 0.00 0.00 0.00 0.00 — — — — —
Share-based compensation (USD) 6.01M 5.1M 2.64M 3.32M 3.97M 3.69M 7.27M 7.36M 7.12M 14.5M
Free cash flow (OCF - PPE - intangibles) (USD) — -14.1M -15.4M -24.2M — — -44.7M — — —
Income detail
Research and development expense (USD) 12.1M 17.3M 19.1M 14.5M 15M 32.5M 43.8M 55.7M 61.5M 53.8M
↳ 5y CAGR +448.1% +254.0% +25.2% +9.7% +21.8% +20.5% +23.9% +33.6% +29.1%
Total comprehensive income (USD) — — — — — -41.1M -52.1M -68.2M -74.3M -77.7M
Comprehensive income to owners (USD) — — — — — -41.1M -52.1M -68.2M -74.3M -77.7M
Reported Sep 10, 2019 Sep 10, 2019 Oct 13, 2020 Oct 13, 2020 Sep 15, 2021 Sep 14, 2023 Sep 14, 2023 Sep 19, 2024 Sep 17, 2025 Sep 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Transaction led by Frazier Life Sciences with participation from new and existing funds

REDWOOD CITY, Calif., November 13, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced the pricing of an underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,800,000 shares of common stock at an offering price of $3.869 per pre-funded warrant, which represents the per share offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Rezolute from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $100 million. The offering is expected to close on or about November 16, 2026, subject to the satisfaction of customary closing conditions.

Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation

Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026

REDWOOD CITY, Calif., November 13, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary results from a November 5th data evaluation.

The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia.

November 05, 2026 4:05 pm EST Download as PDF

Related Documents

10-Q HTML PDF XBRL Zip

REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026.

Tumor HI

  • upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing.
    • Enrollment is complete and topline results are expected by mid-December 2026.
  • Earlier this year, the Company announced that 7 of the 8 participants enrolled in the first half of the study met the responder criterion for the study’s primary endpoint.
    • Each of these participants also achieved complete discontinuation of intravenous glucose with the administration of ersodetug.
    • Ersodetug has been well-tolerated in the study thus far, with no drug-related safety findings reported.
    • The eighth participant in the first half of the study discontinued study drug shortly after enrollment in favor of pursuing hospice care at home, where they died one week later due to cancer progression. The Company considers this participant as a non-responder, for purposes of the primary endpoint.

Congenital HI

  • In October 2026, the Company provided an update that the U.S. Food and Drug Administration (FDA or the Agency) has reviewed additional study data provided by the Company at the Agency’s request.
  • The Agency recommended the Company file for review under a Biologics License Agreement (BLA) for congenital HI after holding a pre-BLA meeting.
    • As previously reported, sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI, demonstrated glycemic improvements, but did not meet the primary endpoint because the reductions in hypoglycemia events by finger-stick self-monitored blood glucose (SMBG) were not statistically significant compared to placebo. However, consistent and clinically relevant improvements in hypoglycemia were observed across multiple CGM-based hypoglycemia endpoints in both treatment arms.
    • The open-label extension (OLE) phase of the sunRIZE study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies.

Business Update

  • On October 29, 2026, the Company participated in a virtual Q&A as part of Guggenheim’s Healthcare Spotlight Series. The discussion focused on commercial outlook and launch strategy for ersodetug. Key highlights include:
    • Potential $5 billion combined market opportunity.
    • Plan to submit a BLA for ersodetug for one or potentially both indications in 2027.

First Quarter Fiscal 2027 Financial Results

Cash, cash equivalents and investments in marketable securities were $90.0 million as of September 30, 2026, compared with $107.8 million as of June 30, 2026.

Research and development (R&D) expenses were $12.8 million for the first quarter of fiscal 2027, compared with $13.1 million for the same period a year ago. The decrease was primarily due to decreased manufacturing costs for ersodetug and patient affairs costs, partially offset by increased employee-related stock-based compensation expense. R&D expenses include $1.5 million of share-based compensation expense for the first quarter of fiscal 2027, compared with $1.2 million for the same period a year ago.

General and administrative (G&A) expenses were $6.6 million for the first quarter of fiscal 2027, compared with $6.7 million for the same period a year ago. The decrease was primarily attributable to a decrease in professional fees, partially offset by increased employee-related stock-based compensation expense. G&A expenses include $1.8 million of share-based compensation expense for the first quarter of fiscal 2027, compared with $1.4 million for the same period a year ago.

Net loss was $18.5 million for the first quarter of fiscal 2027 compared with a net loss of $18.2 million for the same period a year ago.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of hyperinsulinism (HI), including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. 

About Rezolute, Inc.

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com . 

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, statements regarding the potential safety, efficacy and therapeutic and commercial potential of ersodetug for the treatment of hypoglycemia caused by hyperinsulinism; the timing and results of the Phase 3 upLIFT study of ersodetug in tumor HI, including our expectation to announce topline results by mid-December 2026; the predictive nature of the CGM data and other findings from the sunRIZE study and its ongoing open-label extension as they relate to the potential efficacy of ersodetug in treating hypoglycemia; the persuasiveness of the additional study data reviewed by FDA and the possibility of FDA agreeing to advance the congenital HI program notwithstanding the lack of statistical significance for the primary endpoint in the sunRIZE study; the Company’s plans and expectations regarding a pre-BLA meeting and the potential submission of a Biologics License Application (BLA) for ersodetug for one or both of tumor HI and congenital HI in 2027; the potential safety, efficacy and therapeutic potential of ersodetug for treating refractory hypoglycemia caused by any form of HI; and the commercial outlook and launch strategy for ersodetug, including the potential $5 billion combined market opportunity. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. With respect to congenital hyperinsulinism, although FDA has recommended that the Company file a BLA for review for congenital HI after holding a pre-BLA meeting, there can be no assurance that FDA will agree that the totality of evidence from the sunRIZE program demonstrates a clinically meaningful benefit or is sufficient to support approval of ersodetug for congenital HI. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Rezolute Contacts:

Christen Baglaneas
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
[email protected]
508-272-6717

Carrie McKim
Rezolute, Inc.
1411 Broadway, 16th Floor
New York, NY 10018
[email protected]
336-608-9706

Rezolute, Inc.
Condensed Consolidated Financial Statements Data
(in thousands, except per share data)
Three Months Ended
September 30,
2026 2025
Condensed Consolidated Statements of Operations Data:
Operating expenses:
Research and development $ 12,807 $ 13,149
General and administrative 6,578 6,668
Total operating expenses 19,385 19,817
Loss from operations (19,385 ) (19,817 )
Non-operating income, net 898 1,667
Net loss $ (18,487 ) $ (18,150 )
Basic and diluted net loss per common share $ (0.18 ) $ (0.18 )
Shares used to compute basic and diluted net loss per common share 104,778 103,423
September 30, June 30,
2026 2026
Condensed Consolidated Balance Sheets Data:
Cash and cash equivalents $ 8,150 $ 10,615
Investments in marketable debt securities 81,849 97,186
Working capital 84,370 99,093
Total assets 96,010 112,849
Accumulated deficit (499,929 ) (481,442 )
Total stockholders’ equity 85,948 100,687

Primary Logo

Source: Rezolute, Inc.

Released November 5, 2026

Stay Connected

Visit us on LinkedIn Visit us on X Visit us on Facebook

Footer logo

Join our passionate and dedicated team to make a difference for patients.

SEE OPEN JOBS

©2026 Rezolute, Inc. All rights reserved. Privacy Policy Terms of Use

Made by 22 Fillmore

Prompts

Rezolute, Inc. (ticker RZLT), listed in United States.

Company History

Date Change Detail
Dec 19, 2017 Renamed ANTRIABIO, INC. → REZOLUTE, INC.
Dec 11, 2012 Renamed FITS MY STYLE INC → ANTRIABIO, INC.

ETFs Holding Rezolute, Inc.

ETF Weight in ETF Shares Market value As of
JSML 0.42% 320,855 $ 1.514M Jul 31, 2026
RUSC 0.23% 34,610 $ 179.972K Jun 30, 2026
FSEG 0.09% 992 $ 5,158.40 Jun 30, 2026
VFMO 0.08% 328,494 $ 1.541M Aug 31, 2026
FESM 0.01% 155,117 $ 806.608K Jun 30, 2026
RESM 0.01% 94 $ 488.80 Jun 30, 2026
DFAS 0.01% 462,722 $ 1.791M Nov 12, 2026
DFSU 0.00% 12,923 $ 50.012K Nov 12, 2026
DXUV 0.00% 19,300 $ 74.691K Nov 12, 2026
DFAU 0.00% 19,647 $ 76.034K Nov 12, 2026
DFAC 0.00% 50,203 $ 194.286K Nov 12, 2026
DCOR 0.00% 13,711 $ 53.062K Nov 12, 2026
DFUS 0.00% 6,281 $ 24.307K Nov 12, 2026
AVSC 0.00% 2,142 $ 7,668.36 Nov 16, 2026